Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock


An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan Mcdermid | Reuters

Eli Lilly‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S&P 500’s performance over the past three years.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *